News >

Neratinib Regimens Elicit CNS Responses in HER2+ Breast Cancer

Ellie Leick
Published: Wednesday, Jan 15, 2020

Nancy U. Lin, MD, associate chief in the Division of Breast Oncology at the Susan F. Smith Center for Women's Cancers, director of the Metastatic Breast Cancer Program, senior physician at Dana-Farber Cancer Institute, and an associate professor of medicine at Harvard Medical School

Nancy U. Lin, MD

A combined analysis of data from the NALA, NEfERT-T, and TBCRC 022 trials demonstrated potential with neratinib (Nerlynx) regimens for patients with HER2-positive breast cancer who have brain metastases, explained Nancy U. Lin, MD.
... to read the full story
To Read the Full Story



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x